Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab with CHOP-14 in Elderly NHL
NCT00028717Phase 3Unknown
- Sponsor
- Commissie voor Klinisch Toegepast Onderzoek
- Start
- Feb 2001
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab in non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Commissie voor Klinisch Toegepast Onderzoek. Primary endpoint: Event-free survival. Status: unknown.
02
Drugs
rituximab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00028717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00028717.